Swissmedic has issued a Health Professional Communication (HPC) mandating an amendment to the contraindications for lisdexamfetamine dimesylate. The drug will now be contraindicated for patients diagnosed with pheochromocytoma, a condition involving tumors that can cause excessive catecholamine release. This update is necessary because sympathomimetic stimulants like lisdexamfetamine can exacerbate this condition, leading to potentially fatal consequences.

The product information for lisdexamfetamine dimesylate-containing medicines will be updated. Specifically, the 'Contraindications' section will include 'Pheochromocytoma,' and the patient information leaflet will add a warning against taking the medication if the patient suffers from this condition. This change requires immediate attention from drug manufacturers to update their labeling and from healthcare providers to ensure appropriate patient counseling and prescription practices.